EMA Authorised: Ozurdex (dexamethasone) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Ozurdex (dexamethasone intravitreal implant) for the treatment of macular edema and uveitis. The decision was issued to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Uveitis

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

Status: Authorised. Therapeutic area: Macular Edema;Uveitis. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 18/09/2025